Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/rcr2.744 http://scihub22266oqcxt.onion/10.1002/rcr2.744 33815804!8008274!33815804     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Respirol+Case+Rep 2021 ; 9 (5): e00744 Nephropedia Template TP {{tp|p=33815804|t=2021. Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019 |pdf=|usr=}}{{33815804}} gab.com Text Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019 JO: Respirol Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=33815804 #FOAvip A 78-year-old Japanese woman with no smoking history suffered from near-fatal coronavirus disease 2019 (COVID-19) requiring four-week invasive mechanical ventilation, with subsequent radiological features of pulmonary fibrosis. Although methylprednisolone gradually improved her respiratory condition, her oxygenation and exercise tolerance had drastically deteriorated, necessitating high-flow nasal cannula oxygen therapy. In parallel with tapering systemic steroid, the patient was treated with nintedanib. Three months later, the patient was able to walk with a walking aid using oxygen at 4 L/min. The present case is an indication that nintedanib might provide a novel therapeutic approach for managing post-COVID-19 fibrosis, although further studies are warranted. Twit Text FOAVip Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019 ????Respirol Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=33815804 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33815804 #FOAvip English Wikipedia <ref>{{Cite pmid|33815804}}</ref> Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019 #MMPMID33815804 Ogata H; Nakagawa T; Sakoda S; Ishimatsu A; Taguchi K; Kadowaki M; Moriwaki A; Yoshida M Respirol Case Rep 2021[May]; 9 (5): e00744 PMID33815804show ga A 78-year-old Japanese woman with no smoking history suffered from near-fatal coronavirus disease 2019 (COVID-19) requiring four-week invasive mechanical ventilation, with subsequent radiological features of pulmonary fibrosis. Although methylprednisolone gradually improved her respiratory condition, her oxygenation and exercise tolerance had drastically deteriorated, necessitating high-flow nasal cannula oxygen therapy. In parallel with tapering systemic steroid, the patient was treated with nintedanib. Three months later, the patient was able to walk with a walking aid using oxygen at 4 L/min. The present case is an indication that nintedanib might provide a novel therapeutic approach for managing post-COVID-19 fibrosis, although further studies are warranted. äNintedanib treatment for pulmonary fibrosis after coronavirus disease (epmc).pdf DeepDyve Pubget Overpricing